By Fineline Cube Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) to initiate a Phase I clinical trial for its pipeline candidate HLX48, an EGFR/c-Met bispecific antibody-drug conjugate (ADC). The first-in-human (FIH) study will evaluate the molecule in patients with advanced/metastatic solid tumors.
Regulatory Milestone & Clinical Development Framework
| Component | Detail |
|---|---|
| Company | Shanghai Henlius Biotech Inc. (HKG: 2696) |
| Regulatory Authority | Therapeutic Goods Administration (TGA), Australia |
| Trial Phase | Phase I (First-in-Human) |
| Patient Population | Advanced/metastatic solid tumors |
| Geographic Strategy | Australia as international development hub |
| Development Stage | Early clinical |
Drug Profile & Dual-Targeting Mechanism of Action
- Molecule: EGFR/c-Met bispecific antibody-drug conjugate (ADC)
- Dual Binding: Simultaneously binds with high affinity to EGFR and c-Met on tumor cell surfaces
- Ligand Blockade: Prevents interaction with epidermal growth factor (EGF) and hepatocyte growth factor (HGF)
- Synergistic Inhibition: Blocks two key tumor growth and survival signaling pathways at the source
- Resistance Overcoming: Potential to address EGFR-targeted therapy resistance caused by mechanisms like MET amplification
- Preclinical Evidence: Demonstrated significant anti-tumor activity across multiple tumor models
Strategic Significance & Competitive Differentiation
Bispecific ADC Innovation
- Novel Target Combination: EGFR/c-Met dual targeting addresses complementary oncogenic pathways
- Enhanced Specificity: Bispecific design potentially improves tumor selectivity over monospecific ADCs
- Payload Delivery: ADC format enables targeted cytotoxic payload delivery to dual-positive tumor cells
- Resistance Management: Addresses key clinical challenge of acquired resistance to EGFR inhibitors
International Development Strategy
- Australia Selection: Leverages Australia’s efficient regulatory pathway and strong clinical trial infrastructure
- Global Ambitions: TGA approval represents first step toward broader international development
- Portfolio Diversification: Expands Henlius’s oncology pipeline beyond biosimilars into novel targeted therapies
Market Context & Therapeutic Opportunity
EGFR/c-Met Target Rationale:
- EGFR Overexpression: Common in multiple solid tumors including lung, colorectal, and head/neck cancers
- c-Met Amplification: Emerging resistance mechanism to EGFR-targeted therapies
- Co-expression Patterns: Significant patient populations exhibit dual EGFR/c-Met positivity
- Unmet Need: Limited effective options for patients developing resistance to current EGFR inhibitors
Competitive Landscape:
- Bispecific ADC Space: Emerging therapeutic class with limited clinical-stage candidates
- First-Mover Potential: Early clinical entry could establish significant competitive advantage
- Combination Potential: Future opportunities for combination with other targeted therapies or immunotherapies
Development Timeline & Commercial Outlook
The Phase I trial will assess safety, tolerability, pharmacokinetics, and preliminary efficacy of HLX48. Given the strong preclinical rationale and unmet medical need in EGFR-resistant populations, successful early clinical data could position HLX48 for accelerated development pathways.
Success would represent a significant milestone in Henlius’s strategic evolution from primarily biosimilars-focused company to innovative oncology drug developer with proprietary assets addressing high-value therapeutic areas.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of HLX48. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market conditions.-Fineline Info & Tech